ADP 050
Alternative Names: ADP-050Latest Information Update: 11 Mar 2024
At a glance
- Originator Alector
- Class Antiparkinsonians
- Mechanism of Action Glycosylceramidase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lewy body disease; Parkinson's disease
Most Recent Events
- 31 Dec 2023 Alector has patent protection for more than 20 targets and/or technologies before December 2023
- 31 Dec 2023 Alector has patents pending for more than 20 targets and/or technologies before December 2023
- 31 Dec 2023 Preclinical trials in Lewy body disease in USA (unspecified route) before December 2023